Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price hit a new 52-week high on Monday . The company traded as high as $48.86 and last traded at $47.68, with a volume of 237795 shares. The stock had previously closed at $47.79.
Gemini Therapeutics Trading Down 0.2 %
The stock’s 50-day moving average price is $46.99 and its 200-day moving average price is $43.53. The company has a market capitalization of $2.07 billion, a P/E ratio of -47.79 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
See Also
- Five stocks we like better than Gemini Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Differences Between Momentum Investing and Long Term Investing
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Financial Services Stocks Investing
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
